RxDoctor Payments Data

Michael Bernstein, MD

Pulmonary Disease · Stamford, CTNPI 1538376793

Payments from drug & device makers

$6,763in general payments, 2019–2025

Across 26 payments — averaging $260.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Johnson & Johnson$439
  • Noah Medical Corporation$397
  • Covidien LP$188
  • AstraZeneca$85
  • Abbott$69
  • plus $129 from 4 others

What the payments were for

  • Travel & lodging$1,80527%
  • Food & beverage$95814%
  • Education$4,00059%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,763 in reported general payments places this provider in the 70th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$138,190
Medicare patients
485
Services billed
1,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$44,822
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$32,142
Breo ElliptaFluticasone/Vilanterol49$30,146
Incruse ElliptaUmeclidinium Bromide27$11,495
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$3,643
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,250
SymbicortBudesonide/Formoterol Fumarate12$3,226
Wixela InhubFluticasone Propion/Salmeterol18$2,605
Ventolin HfaAlbuterol Sulfate22$1,452
Albuterol Sulfate HfaAlbuterol Sulfate66$1,282
Fluticasone Propionate19$453
Olmesartan Medoxomil13$329
Prednisone23$191
Metoprolol Succinate13$184
Amlodipine Besylate13$149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$43$118,605168 claims
AstraZenecaSymbicort$85$3,22612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →